Critical challenges and advances in recombinant adeno‐associated virus (rAAV) biomanufacturing
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Gene therapy is a promising therapeutic approach for genetic and acquired diseases nowadays. Among DNA delivery vectors, recombinant adeno‐associated virus (rAAV) is one of the most effective and safest vectors used in commercial drugs and clinical trials. However, the current yield of rAAV biomanufacturing lags behind the necessary dosages for clinical and commercial use, which embodies a concentrated reflection of low productivity of rAAV from host cells, difficult scalability of the rAAV‐producing bioprocess, and high levels of impurities materialized during production. Those issues directly impact the price of gene therapy medicine in the market, limiting most patients’ access to gene therapy. In this context, the current practices and several critical challenges associated with rAAV gene therapy bioprocesses are reviewed, followed by a discussion of recent advances in rAAV‐mediated gene therapy and other therapeutic biological fields that could improve biomanufacturing if these advances are integrated effectively into the current systems. This review aims to provide the current state‐of‐the‐art technology and perspectives to enhance the productivity of rAAV while reducing impurities during production of rAAV.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A subcellular map of the human proteome
Thul, P. J., Åkesson, L., Wiking, M., Mahdessian, D., Geladaki, A., Ait Blal, H., Alm, T., Asplund, A., Björk, L., Breckels, L. M., et al. (2017) · Science · doi:10.1126/science.aal3321 · Cited by 2,813
Adeno-associated virus vector as a platform for gene therapy delivery
Wang, D., Tai, P. W. L., & Gao, G. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0012-9 · Cited by 2,444
A draft map of the human proteome
Kim, M.-S., Pinto, S. M., Getnet, D., Nirujogi, R. S., Manda, S. S., Chaerkady, R., Madugundu, A. K., Kelkar, D. S., Isserlin, R., Jain, S., et al. (2014) · Nature · doi:10.1038/nature13302 · Cited by 2,198
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Mass-spectrometry-based draft of the human proteome
Wilhelm, M., Schlegl, J., Hahne, H., Gholami, A. M., Lieberenz, M., Savitski, M. M., Ziegler, E., Butzmann, L., Gessulat, S., Marx, H., et al. (2014) · Nature · doi:10.1038/nature13319 · Cited by 1,820 · cited 1×
“The human proteome maps have been drafted over the last decade (Kim et al., 2014), including those based on mass‐spectrometry data (Wilhelm et al., 2014).”
BackgroundDunbar, C. E., High, K. A., Joung, J. K., Kohn, D. B., Ozawa, K., & Sadelain, M. (2018) · Science · doi:10.1126/science.aan4672 · Cited by 1,410 · cited 2×
“Since the release of the first gene therapy product, Glybera, in 2012 for the treatment of hereditary lipoprotein lipase deficiency (LPLD), gene therapy has since gained worldwide attention (Dunbar et al., 2018).”
BackgroundAdeno-Associated Virus (AAV) as a Vector for Gene Therapy
Naso, M. F., Tomkowicz, B., Perry, W. L., & Strohl, W. R. (2017) · BioDrugs · doi:10.1007/s40259-017-0234-5 · Cited by 1,362 · cited 1×
“…rounds or coupling with other techniques like diafiltration, the drawbacks of this method are low scalability (Robert et al., 2017; Schnödt & Büning, 2017), the physiochemical effect on the particles, and high time‐consuming process (Kramberger et al., 2015; Naso et al., 2017; Qu et al., 2015).”
MethodEngineering adeno-associated virus vectors for gene therapy
Li, C., & Samulski, R. J. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-019-0205-4 · Cited by 1,175 · cited 1×
“Proper capsid design and capsid engineering can effectively improve the rAAV transduction efficiency, thus lowering the dose required for disease treatment (Büning & Srivastava, 2019; Li & Samulski, 2020).”
BackgroundBaculovirus as versatile vectors for protein expression in insect and mammalian cells
Kost, T. A., Condreay, J. P., & Jarvis, D. L. (2005) · Nature Biotechnology · doi:10.1038/nbt1095 · Cited by 1,014
Biopharmaceutical benchmarks 2018
Walsh, G. (2018) · Nature Biotechnology · doi:10.1038/nbt.4305 · Cited by 978 · cited 2×
“Proteome has been widely utilized in studying monoclonal antibody (mAb) producing CHO cell lines (Strasser, Farrell, et al., 2021; Walsh, 2018), which currently has been engineered and optimized for higher productivity based on earlier proteome investigations.”
BackgroundMethod
Cited by
Manufacturing cell and gene therapies: challenges in clinical translation
Lee, N. K., & Chang, J. W. (2024) · Annals of Laboratory Medicine · doi:10.3343/alm.2023.0382 · Cited by 78
“Although the use of stable producer cell lines may serve clinically beneficial purposes, several points must be considered during manufacturing to facilitate clinical translation, such as contamination with helper viruses or cytotoxicity induced by vector components required for AAV production [41].”
BackgroundPerfusion‐Based Production of rAAV via an Intensified Transient Transfection Process
Nguyen, T. N. T., Park, D., Canova, C. T., Sangerman, J., Srinivasan, P., Ou, R. W., Barone, P. W., Neufeld, C., Wolfrum, J. M., Springs, S. L., et al. (2025) · Biotechnology and Bioengineering · doi:10.1002/bit.28967 · Cited by 10
Kuchemüller, K. B., Austerjost, J., Machleid, R., Roßkamp, A., Niemann, J., & McCready, C. (2026) · Bioprocess and Biosystems Engineering · doi:10.1007/s00449-026-03362-2
Metadata
- Authors
- Fu, Q., Polanco, A., Lee, Y. S., & Yoon, S.
- Venue
- Biotechnology and Bioengineering
- Publisher
- Wiley
- Published
- 2023-05
- Volume
- 120
- Issue
- 9
- Pages
- 2601-2621
- ISSN
- 0006-3592 (ISSN-L)
- 1097-0290
- OpenAlex
- W4367600488
- Cited by
- 79
- References
- 35
- FWCI
- 11.57
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.